keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates

keyword
https://www.readbyqxmd.com/read/29778637/total-mandibulectomy-defect-in-the-setting-of-chronic-bisphosphonate-use
#1
Ameya A Jategaonkar, Arvind K Badhey, Fiyin Sokoya, Sameep Kadakia, Steven Mudrovich, Yadranko Ducic
Bisphosphonates are among several drugs known in modern medicine to have a potentially deleterious effect on the mandible with chronic use. While purportedly causing a necrotic reaction in the bone, the complete mechanism is not fully elucidated yet as cases are quite rare in the general public. Despite the esoteric nature of this entity, patients suffering from bisphosphonate induced necrosis have a complicated and prolonged course often involving varying degrees of mandibular debridement with severe cases requiring reconstruction...
May 16, 2018: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/29774416/restoration-of-proximal-periprosthetic-bone-loss-by-denosumab-in-cementless-total-hip-arthroplasty
#2
Satoshi Nagoya, Kenji Tateda, Shunichiro Okazaki, Ima Kosukegawa, Junya Shimizu, Toshihiko Yamashita
Denosumab contributed to the restoration of proximal periprosthetic bone loss around the femoral stem that were measured using a DEXA, especially in zone 7, at 1 year after cementless THA in elderly osteoporotic patients. INTRODUCTION: Although bone quality is an important issue in elderly osteoporotic patients who underwent total hip arthroplasty (THA) with a cementless stem, periprosthetic bone mineral density (BMD) in the proximal femur has been reported to be decreased by 15-40% postoperatively...
May 17, 2018: European Journal of Orthopaedic Surgery & Traumatology: Orthopédie Traumatologie
https://www.readbyqxmd.com/read/29774402/subtrochanteric-and-diaphyseal-femoral-fractures-in-hypophosphatasia-not-atypical-at-all
#3
F Genest, L Seefried
Risk for subtrochanteric and diaphyseal femoral fractures is considered increased in patients with hypophosphatasia (HPP). Evaluating a large cohort of HPP patients, we could for the first time quantify the prevalcence and identify both morphometric features as well as predisposing factors for this complication of severe HPP. INTRODUCTION: Subtrochanteric and diaphyseal femoral fractures have been associated with both, long-term antiresorptive treatment and metabolic bone disorders, specifically Hypophosphatasia (HPP)...
May 17, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29762110/surgical-complications-associated-with-atypical-femur-fractures-attributed-to-bisphosphonate-use
#4
Douglas S Schultz, Henry M Gass, William R Barfield, Harry A Demos, Langdon A Hartsock
Complications of atypical femur fractures (AFFs) are common. AFFs often receive the same treatment as other femoral fractures; however, there appears to be a higher rate of adverse outcomes. Nine patients sustained a total of 13 AFFs, had documented bisphosphonate use before fracture, and had surgery between 2006 and 2012. Complications included continued pain, surgical revision, nonunion, malunion, deformity, or heterotopic ossification. The overall complication rate was 33.3%, with four of the 12 surgeries performed at this institution resulting in one nonunion and three minor complications...
2018: Journal of Surgical Orthopaedic Advances
https://www.readbyqxmd.com/read/29761837/augmentation-of-the-cytotoxic-effects-of-nitrogen-containing-bisphosphonates-in-hypoxia
#5
Tetsuya Minegaki, Saya Koiki, Yutaro Douke, Chihiro Yamane, Ai Suzuki, Misato Mori, Masayuki Tsujimoto, Kohshi Nishiguchi
OBJECTIVES: Tumour hypoxia is a major obstacle in cancer therapy that leads to poor prognosis. Therefore, the development of cancer treatments that are effective in hypoxia is necessary. Nitrogen-containing bisphosphonates (N-BPs), which are used to treat bone disease, are cytotoxic to several cancer cells in normoxia. Therefore, we investigated the cytotoxicity of N-BPs in cancer cells in hypoxia. METHODS: We studied the cytotoxicities of N-BPs, statins and anticancer drugs in human cancer cells under hypoxic conditions (1% O2 )...
May 15, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29755856/the-guiding-role-of-bone-metabolism-test-in-osteoporosis-treatment
#6
REVIEW
Wei Zhang, Guo-Ji Yang, Shi-Xian Wu, Dong-Qing Li, Ying-Bo Xu, Cheng-Hong Ma, Jun-Ling Wang, Wei-Wen Chen
Osteoporosis (OP) and osteoporotic fractures are becoming a serious health care issue in the world. Calcium and vitamin D are the basic treatment for osteoporosis. Nonetheless, they do not effectively reduce the incidences of fracture. Currently approved treatments for osteoporosis include selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab, teriparatide, calcitonin and others. However, the appearance of some adverse effects including atypical fracture and breast cancer has limited long-term treatments above mentioned...
2018: American Journal of Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29752905/paget-s-disease-of-bone-diagnosis-and-treatment-%C3%A2-%C3%A2-%C3%A2-%C3%A2-%C3%A2-%C3%A2
#7
REVIEW
Igor Kravets
Paget's disease of bone is a common bone disorder characterized by disorganized bone remodeling. The most likely etiology is a slow paramyxoviral viral infection in genetically susceptible individuals, however the exact cause is unknown. Enhanced bone resorption due to and increased activity of osteoclasts recruits numerous osteoblasts to resorption sites with large quantities of new bone matrix produced as a result. The accelerated bone resorption and formation are not as closely coupled as in a healthy bone; a disorganized bone tissue is formed...
May 9, 2018: American Journal of Medicine
https://www.readbyqxmd.com/read/29752687/a-phase-ii-study-evaluating-the-efficacy-of-zoledronic-acid-in-prevention-of-aromatase-inhibitor-associated-musculoskeletal-symptoms-the-zap-trial
#8
Cesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, Claire Snyder, Roisin M Connolly, John H Fetting, Daniel F Hayes, Stacie C Jeter, Robert S Miller, Anne Nguyen, Katie Quinlan, Gary L Rosner, Shannon Slater, Anna Maria Storniolo, Antonio C Wolff, Jane Zorzi, Nora Lynn Henry, Vered Stearns
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced incidence of AIMSS. METHODS: In the single-arm trial, the Zoledronic Acid Prophylaxis (ZAP) trial, we compared the incidence of AIMSS against historical controls from the Exemestane and Letrozole Pharmacogenomics (ELPh) trial...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29748107/green-bone-minocycline-induced-discoloration-of-bone-rarely-reported-in-foot-and-ankle
#9
Molly S Judge, J Michael Miller, Michael Lyons
The tetracycline antibiotics incorporate into bone similar to bisphosphonates. Tetracycline stains bone a fluorescent yellow and minocycline, more commonly used for chronic acne, stains bone dark green. Owing to its frequent use, the occurrence of green bone discoloration due to antibiotics in the tetracycline class is well understood. Its pigmentation can be seen through delicate, thin tissue as a dark blue-gray. Histologic inspection of this bone will confirm a benign condition without evidence of bone disease...
May 7, 2018: Journal of Foot and Ankle Surgery: Official Publication of the American College of Foot and Ankle Surgeons
https://www.readbyqxmd.com/read/29747966/a-long-lasting-bisphosphonate-partially-protects-periprosthetic-bone-but-does-not-enhance-initial-stability-of-uncemented-femoral-stems-a-randomized-placebo-controlled-trial-of-women-undergoing-total-hip-arthroplasty
#10
Erik Aro, Niko Moritz, Kimmo Mattila, Hannu T Aro
Low bone quality may compromise the success of cementless total hip arthroplasty in high-risk patients such as elderly women. Zoledronic acid is a long-lasting antiresorptive agent, which is known to reduce short-term periprosthetic bone loss. However, its effect on femoral stem stability is not well known. Forty-nine female patients with a mean age of 68 years (range, 51-85 years) scheduled to undergo cementless total hip arthroplasty due to osteoarthritis were randomized in this double-blind, placebo-controlled trial to receive a single postoperative infusion of zoledronic acid or placebo...
May 3, 2018: Journal of Biomechanics
https://www.readbyqxmd.com/read/29747794/recommendations-for-the-prevention-of-bisphosphonate-related-osteonecrosis-of-the-jaw-a-systematic-review
#11
Flávia Aparecida Cariolatto, Julia Carelli, Taís de Campos Moreira, Ricardo Pietrobon, Clarissa Rodrigues, Ana Paula Bonilauri Ferreira
OBJECTIVES: The aim of this study was to assess the quality of and outline the differences among recommendations of published clinical practice guidelines (CPGs) for the management of bisphosphonate-associated osteonecrosis of the jaw. METHODS: We conducted a systematic literature search in PubMed, Cochrane, Embase, Web of Science, and Google web site. We selected CPGs supported by a nongovernmental organization or national institutes, related to bisphosphonate-associated osteonecrosis of the jaw in adults, in English language, and dated from January 2008 onward...
June 2018: Journal of Evidence-based Dental Practice
https://www.readbyqxmd.com/read/29746838/national-survey-on-bisphosphonate-related-osteonecrosis-of-the-jaws-in-japan
#12
Takahiko Shibahara, Takamichi Morikawa, Kaori Yago, Hiromitsu Kishimoto, Yutaka Imai, Kenichi Kurita
PURPOSE: From 2011 to 2013, a nationwide retrospective cohort study was conducted by the Japanese Society of Oral and Maxillofacial Surgeons and the Japanese Society of Dentistry for Medically Compromised Patients to assess the development of bisphosphonate (BP)-related osteonecrosis of the jaws (BRONJ) and to elucidate the outcomes and factors associated with remission. MATERIALS AND METHODS: A written questionnaire, including clinical characteristics, management, and outcomes of patients with BRONJ, was sent to 501 institutions...
April 14, 2018: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/29745899/identification-of-a-transporter-complex-responsible-for-the-cytosolic-entry-of-nitrogen-containing-bisphosphonates
#13
Zhou Yu, Lauren E Surface, Chong Yon Park, Max A Horlbeck, Gregory A Wyant, Monther Abu-Remaileh, Timothy R Peterson, David M Sabatini, Jonathan S Weissman, Erin K O'Shea
Nitrogen-containing-bisphosphonates (N-BPs) are a class of drugs widely prescribed to treat osteoporosis and other bone-related diseases. Although previous studies have established that N-BPs function by inhibiting the mevalonate pathway in osteoclasts, the mechanism by which N-BPs enter the cytosol from the extracellular space to reach their molecular target is not understood. Here we implemented a CRISPRi-mediated genome-wide screen and identified SLC37A3 (solute carrier family 37 member A3) as a gene required for the action of N-BPs in mammalian cells...
May 10, 2018: ELife
https://www.readbyqxmd.com/read/29744914/association-of-alendronate-and-risk-of-cardiovascular-events-in-patients-with-hip-fracture
#14
Chor-Wing Sing, Angel Ys Wong, Douglas P Kiel, Elaine Yn Cheung, Joanne Ky Lam, Tommy T Cheung, Esther W Chan, Annie Wc Kung, Ian Ck Wong, Ching-Lung Cheung
The risk of cardiovascular events (CVEs) with alendronate use in real-world hip fracture patients is unknown. This study aimed to investigate the risk of CVE with and without use of alendronate in patients with hip fracture. We conducted a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with hip fracture from 2005 through 2013 were followed until November 6, 2016. Alendronate and other antiosteoporosis medications use during the study period were examined...
May 9, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29744567/low-rates-of-osteoporosis-treatment-after-hospitalization-for-hip-fracture-in-hawaii
#15
E T Nguyen, T Posas-Mendoza, A M Siu, H J Ahn, S Y Choi, S Y Lim
We evaluated osteoporosis treatment and DEXA utilization rates of patients who were admitted for hip fracture in a single healthcare system in Hawaii from 2015 to 2016. We found that osteoporosis treatment and DEXA utilization rates were low, highlighting a critical gap in osteoporosis care after admission for hip fracture. INTRODUCTION: The objective of this study was to evaluate osteoporosis care after an admission for hip fracture at three community hospitals within a single healthcare system in Hawaii...
May 9, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29741296/assessment-and-management-of-bone-health-in-women-with-oestrogen-receptor-positive-breast-cancer-receiving-endocrine-therapy-position-statement-of-the-endocrine-society-of-australia-the-australian-and-new-zealand-bone-mineral-society-the-australasian-menopause
#16
Mathis Grossmann, Sabashini Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks, Helena Teede
OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. METHODS: Representatives appointed by relevant Australian Medical Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing five key questions. RESULTS: Women receiving adjuvant aromatase inhibitors and the subset of premenopausal woman on tamoxifen have accelerated bone loss and increased fracture risk...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29740080/interleukin-17-enhances-bone-morphogenetic-protein-2-induced-ectopic-bone-formation
#17
M Croes, M C Kruyt, W M Groen, K M A van Dorenmalen, W J A Dhert, F C Öner, J Alblas
Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced BMP-2-induced bone formation. Since IL-17 is known to induce osteoclastogenesis, we studied the interactions between IL-17 and BMP-2 in ceramic scaffolds either or not carrying a coating with the bisphosphonate zoledronic acid (ZOL). Histological evaluation revealed that IL-17 alone did not induce any osteoclasts at day 10...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29737412/factors-associated-with-inadequate-responses-to-risedronate-in-japanese-patients-with-osteoporosis
#18
Ryo Okazaki, Ryoichi Muraoka, Masayuki Maehara, Daisuke Inoue
Factors associated with an inadequate response (IR) to bisphosphonates have been reported in many countries, but not in Japan, where the approved dose is half the global dose. We analyzed factors associated with IR to risedronate in Japanese patients with osteoporosis. This was a post hoc analysis of 1261 Japanese osteoporosis patients who received risedronate for 1 year in phase III trials. IR was defined as more than one new vertebral fracture (VF) and/or negative change in lumbar spine bone mineral density (BMD) at 1 year...
May 8, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29734509/efficacy-of-cryoablation-to-control-cancer-pain-a-systematic-review
#19
REVIEW
Laura Ferrer-Mileo, Ana Isabel Luque Blanco, Jesús González-Barboteo
CONTEXT: The use of opioids to control cancer pain could be insufficient. Interventional techniques such as a cryoablation have emerged as alternatives to opioids. OBJECTIVES: To summarize the current scientific evidence on the use of cryoablation to control cancer pain. METHODS: A systematic search of the Scopus, Pubmed, and Cochrane databases was performed. All articles published before December 31, 2015 whose title or abstract specified cancer pain control as endpoint were selected...
May 7, 2018: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/29729949/prevention-of-glucocorticoid-induced-osteoporosis-clinical-audit-to-evaluate-the-implementation-of-national-osteoporosis-guideline-group-2017-guidelines-in-a-primary-care-setting
#20
Matthew Carter
Treatment with glucocorticoids is the leading cause of drug-induced osteoporosis. National Osteoporosis Guideline Group (NOGG) 2017 guidelines advise a case-finding strategy for patients at risk. The aims of the audit were to evaluate the implementation of the NOGG 2017 guidelines for patients receiving long-term glucocorticoid therapy in a suburban general practice, to instigate changes to ensure 90% of patients are investigated and treated appropriately, and to evaluate impact at a 6-mo re-audit. Reporting Analysis and Intelligence Delivering Results (RAIDR) is a health-care intelligence tool accessing primary care clinical data...
April 12, 2018: Journal of Clinical Densitometry
keyword
keyword
1525
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"